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While endocrine therapy is the mainstay of ER+ breast cancer, the clinical effectiveness 
of these agents is limited by the phenomenon of acquired resistance that is associated 
with disease relapse and poor prognosis. Our previous studies revealed that acquired 
resistance is accompanied by a gain in cellular invasion and migration and also that 
CD44 family proteins are overexpressed in the resistant phenotype. Given the associa-
tion of CD44 with tumor progression, we hypothesized that its overexpression may act 
to promote the aggressive behavior of endocrine-resistant breast cancers. Here, we 
have investigated further the role of two specific CD44 isoforms, CD44v3 and CD44v6, 
in the endocrine-resistant phenotype. Our data revealed that overexpression of CD44v6, 
but not CD44v3, in endocrine-sensitive MCF-7 cells resulted in a gain in EGFR signal-
ing, enhanced their endogenous invasive capacity, and attenuated their response to 
endocrine treatment. Suppression of CD44v6 in endocrine-resistant cell models was 
associated with a reduction in their invasive capacity. Our data suggest that upregulation 
of CD44v6 in acquired resistant breast cancer may contribute to a gain in the aggressive 
phenotype of these cells and loss of endocrine response through transactivation of the 
EGFR pathway. Future therapeutic targeting of CD44v6 may prove to be an effective 
strategy alongside EGFR-targeted agents in delaying/preventing acquired resistance in 
breast cancer.
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inTrODUcTiOn
Over two-thirds of breast cancers express the estrogen receptor and are, likely to respond to 
endocrine therapies exemplified by tamoxifen (1, 2). However, despite the undoubted improve-
ments brought by such treatments, acquired resistance to these agents remains a significant 
problem with resistant tumors frequently recurring at distant sites (3). Increasingly, evidence 
suggests that a gain in aggressive, metastatic cell functions accompanies acquisition of resistance 
(4–7) although the mechanisms underlying this are unclear. Thus, a greater understanding of the 
molecular pathways associated with resistance is needed in order to highlight better therapeutic 
opportunities. To this end, we have previously reported that acquired tamoxifen resistance in 
2Bellerby et al. CD44v6 and Endocrine Resistance
Frontiers in Oncology | www.frontiersin.org June 2016 | Volume 6 | Article 145
breast cancer is accompanied by the overexpression of the 
CD44 transmembrane receptor protein that appears to con-
tribute to their aggressive phenotype through modulation of 
growth factor receptor signaling.
A challenge to developing therapies against CD44 lies in the fact 
that CD44 represents a large family of variant isoforms expressed 
through alternative splicing of the CD44 gene and controversy 
exists as to which isoforms are tumor-protective and which may 
act to promote tumor progression (8, 9). However, the majority 
of studies appear to have focused on CD44v3 and CD44v6 and 
their role as promoters of tumor migration, invasion, and spread 
(10–13). CD44v6 is specifically implicated in the tumorigenesis 
and migration of tumor cells during metastasis (14, 15) while 
overexpression of CD44v6 is suggested to predict overall survival 
(OS) and disease-free survival (DFS) in breast and other cancers 
(16–18). A number of studies also support an association between 
CD44v3 and invasion (10) and metastasis (19, 20). Interestingly, 
in many of these cases, it is the co-expression of CD44 isoforms 
alongside other growth factor receptors that confers a poor 
prognostic signature.
While our previous study looked at global CD44 expression, 
identifying specific CD44 variants that may play a role in drug 
resistance represents an important goal with respect to identi-
fying specific elements that may represent future therapeutic 
opportunities. In this study, we provide data supporting the 
hypothesis that the CD44v6 rather than CD44v3 acts to limit 
endocrine response and promote tumor progression through 
EGFR transactivation in breast cancer cells. Importantly, our 
translational studies further suggest that CD44v6 and EGFR 
co-expression may represent an important prognostic marker for 
ER+ breast cancers.
MaTerials anD MeThODs
cell culture
Endocrine responsive MCF-7 cells were maintained in phenol-
red free RPMI with l-glutamine (200  mM) containing 5% 
(v/v) fetal calf serum and antibiotics [penicillin (10  IU/ml), 
streptomycin (10 μg/ml), and fungizone (2.5 μg/ml)]. Tamoxifen-
resistant (Tam-R) and fulvestrant-resistant (Fas-R) cells (4, 7) 
were cultured in phenol-red free RPMI containing 5% (v/v) 
charcoal-stripped steroid depleted fetal calf serum, antibiotics as 
above and supplemented with 4-hydroxy tamoxifen (100  mM) 
or fulvestrant (100 mM), respectively. Antibodies were used that 
recognized CD44 Std (Clone 156-3C11; Fisher Scientific), anti-
CD44v3 (Clone VFF-327) and anti-CD44v6 (Clone 2F10) (both 
R&D Systems), and RHAMM (Abcam). All other antibodies were 
purchased from Cell Signaling Technologies. All other reagents 
were from Sigma Ltd. (Dorset, UK), unless otherwise stated.
Microarray analysis
Triplicate RNA samples from MCF-7, Tam-R, and Fas-R cells were 
microarrayed using Affymetrix Human Genome U133A gene 
chips with subsequent median normalization across all datasets 
and log transformation using Genesifter. Heatmap profiles and 
log2 intensity plots were generated to visualize gene expression 
changes across all cell models. The genes analyzed by microarray 
were as follows: CD44, HMMR (the gene corresponding to the 
RHAMM protein), stabilin 2 (STAB-2), lymphatic vessel endothe-
lial receptor 1 (LYVE-1), toll-like receptor 4 (TL4), intracellular 
adhesion molecule-1 (ICAM-1), and versican (VCAN). Statistical 
analysis of probe expression between cells was performed using 
ANOVA with Tukey post hoc analysis.
rT-Pcr
mRNA was isolated from MCF-7, Tam-R, and Fas-R cells 
and reverse-transcribed to cDNA using primers correspond-
ing to the standard form of CD44 (sF: 5′GACACATATTGG 
CTTCAATGCTTCAGC3′; sR: GATGCCAAGATGATCAGCCA 
TTCTGGAAT3′), CD44 variant 3 (sF:5′ AGTCACAGACCTGC 
CCAATGCCTTT3′; sR: 5′GGTGTCTGTCTCTTTCATCTTCA 
TTTTTCTTCATTT3′), variant 6 (sF: 5′ CAACGGAAGAAAC 
AGCTACC3′; sR: 5′CCTGTTGTCGAATGGGAGTC3′), and 
β-actin (sF: 5′GGAGAATGATCTTGATCTT3′ sR 5′CCTTCCT 
TGGGCATGGAGTCCT3′). All PCRs were performed in a 
 semi-quantitative manner using 27–30 cycles so that products 
were in a linear range of amplification. PCR products were sepa-
rated and visualized on a 1% agarose gel using ethidium bromide 
and photographed (representative images are shown from a 
minimum of three separate experiments).
cell lysis and Western Blotting
Log phase cultures were lysed in Triton X100 lysis buffer con-
taining protease inhibitors. Clarified supernatants were boiled in 
sample buffer and equal amounts of proteins and resolved by 8% 
SDS-PAGE. Separated proteins were immobilized on nitrocel-
lulose membranes and probed with antibodies against CD44 Std, 
CD44v6, CD44v3, RHAMM, and the activated forms of EGFR 
(Y1068), ErbB2 (Y1248), Met (Y1234/1235), FAK (Y397), MAPK 
(T202/Y204), AKT (S473), Src (Y416), and GAPDH. Bound 
primary antibodies were detected by HRP-conjugated second-
ary anti-mouse or anti-rabbit IgG (Fisher Scientific, UK) and 
subsequent chemiluminescence analysis. Representative blots are 
shown from a minimum of three separate experiments.
immunocytochemistry
Log-phase cultures of MCF-7, Tam-R, and Fas-R cells were 
fixed with 2.5% phenol formal saline and stained with primary 
antibodies. Antibody detection was performed with Dako mouse 
EnVision (peroxidase-labeled polymer) for 30  min and DAB 
chromogen, counterstaining with 1% methyl green. Photographs 
were taken of cells at ×40 magnification. Plasma membrane and 
cytoplasm percentage positivity were assessed to derive a total 
H-score value for each cell line.
immunohistochemical analysis of cD44v6 
expression in clinical Breast cancer
Tumor tissue was available from patients with histologically 
proven breast cancer that presented for surgery at Nottingham 
City Hospital between 1984 and 1987. This series comprised 
part of an historical breast cancer collection with approval for 
use without further patient consent [approved ethics application 
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C108030; Nottingham Research Ethics Committee (21)]. All 
patients received systemic tamoxifen therapy for locally advanced 
primary carcinoma (>5 cm) and the duration of anti-hormonal 
response and survival from the initiation of therapy monitored for 
each patient by follow-up after surgery. No patient had previously 
received any form of adjuvant endocrine or cytotoxic therapy; the 
median patient age was 54 years (age range 25–77 years). Survival 
and duration of anti-hormone response were measured from com-
mencement of anti-hormone to death or progression on therapy, 
respectively. All patient-related information was anonymized 
and de-identified prior to analysis and the EGFR status of these 
tumors was previously reported (22). Paraffin-embedded tissue 
sections were subject to antigen retrieval by microwaving for 
30  min in 0.1  M citrate buffer (pH  6). Following elimination 
of endogenous peroxide, sections were then blocked with 10% 
normal human serum in PBS for 10  min. Immunostaining 
was then performed using CD44v3 (1/80) and CD44v6 (1/40) 
antibodies for 2 h and antibody detection was performed with 
Dako mouse EnVision (peroxidase-labeled polymer) for 90 min 
and DAB chromogen for 10 min, counterstaining with 1% methyl 
green for 15 min. Negative controls were incubated with mouse 
isotype-specific control IgG (Dako). All sections were assessed 
simultaneously by two observers blinded to the clinical data 
using a dual-viewing light microscope (×40 magnification). 
Matched control slides were checked for non-specific binding 
before assessment of staining intensity. The data were then used 
to construct a CD44v6 H-score for each tumor specimen as 
described below. Statistical analysis [Log Rank (Mantel–Cox)] 
was used to investigate relationship between CD44v6 and EGFR 
and clinicopathological parameters using SPSS version 20. 
Kaplan–Meier survival curves were plotted with a log-rank test to 
analyze the differences between curves. The relative influence of 
CD44v6 and EGFR on survival was examined using multivariate 
analysis according to the non-parametric hazards model of Cox. 
Significance was set at P < 0.05.
evaluation of immunohistochemical 
staining
Staining intensity was evaluated using the H-score as follows: for 
each sample, six fields of view were investigated and allocated a 
value between 0 and 3 dependent on staining intensity (0 = nega-
tive staining, 3 =  strong staining). A total H-score value was 
calculated using the formula: (% at 0) × 0 + (% at 1) × 1 + (% at 
2) × 2 + (% at 3) × 3 to give an overall score ranging between 0 
and 300. Differences between groups were statistically compared 
using the Student’s t-test. Representative images are shown from 
a minimum of three separate experiments.
analysis of cell Migration
A total of 3 ×  104 cells were seeded into the top chambers of 
24-well transwell plates (BD Biosciences, 8.0 μm pore size coated 
with 10 μg/ml fibronectin) with complete media added to the 
bottom chamber. After 24  h of culture, migratory cells (cells 
that had moved to the underside of the membrane) were fixed 
with 3.7% paraformaldehyde, stained with 0.5% crystal violet, 
and counted at ×40 magnification under a light microscope. 
Cell migration was quantified as the mean number of cells 
observed in each of five random fields of view per sample, each 
performed in duplicate over three independent experiments 
and then normalized to the untreated controls (i.e., expressed 
as a percentage of the cells migrating in the control samples). 
Differences between groups were statistically compared using 
the Student’s t-test.
Boyden chamber invasion assay
A total of 3 × 104 cells were seeded onto Matrigel-coated (9.6 mg/
ml) transwell chambers (8 μm pore size) with complete media in 
the bottom chamber. After 72 h of culture, the membranes from 
each transwell insert were removed to allow cells that had invaded 
through the Matrigel layer to the underside of the membrane 
to be fixed with 3.7% paraformaldehyde prior to mounting on 
microscope slides using DAPI-containing vector shield. Cell 
nuclei were counted at ×60 magnification using a fluorescent 
microscope. Cell invasion was quantified as above by counting 
the mean number of cells observed in each of five random fields 
of view per sample, each performed in duplicate and normalizing 
to controls (untreated samples). Differences between groups were 
statistically compared using the Student’s t-test.
coulter counter growth assay
Cell proliferation was determined using the Coulter counter 
growth assay. Briefly, cells were seeded into 24-well plates at 
1.5 × 106 cells/plate and left to adhere for 24 h. Subsequently, fresh 
medium containing treatments as described were added and cells 
were cultured for a further 5 days. Media were then removed from 
the wells and replaced with 1  ml/well trypsin and returned to 
the incubator until cells were in suspension. Trypsin (4 ml/well) 
was added using a sterile syringe and this solution was added to 
6 ml Isoton. The 11 ml Isoton cell suspension was counted twice 
on a Coulter counter (CoulterTM Multisizer II, UK) according 
to manufacturer’s instructions. The average count was multiplied 
by 20 to calculate cells/well. Differences between groups were 
statistically compared using the Student’s t-test.
sirna-Mediated gene suppression in 
endocrine-resistant cells
siRNA knockdown of CD44 (all forms), CD44v6, and RHAMM 
was performed in Tam-R and Fas-R cells as follows. Briefly, log-
phase Tam-R and Fas-R cells were inculbated with 100 nM siRNA/
lipid mixture as per the manufacturer’s protocol (Dharmacon 
Ltd.) for 48 h. Suppression of gene and protein expression was 
confirmed using PCR and Western blotting. After gene suppres-
sion, cells were harvested and used in the assays described above. 
Control experiments used either non-targeting (NT) siRNA or 
transfection lipid only.
Transient Transfection of  
endocrine-sensitive McF-7 cells with 
cD44v3 and cD44v6
Plasmid constructs containing cDNA corresponding to 
CD44v3 and CD44v6 isoforms (in a pPGK-T7/2 vector) were 
provided by Ursula Günthert, Basel University. These constructs 
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FigUre 1 | cD44 isoforms are overexpressed in acquired tamoxifen- and fulvestrant-resistant breast cancer cells. (a) Affymetrix U133A gene 
microarray analysis revealed deregulation of CD44 and its related family members LYVE-1, TL4, STAB-2, ICAM-1, and VCAN in acquired resistant cell models. 
Changes in CD44 gene expression were confirmed by RT-PCR (B), Western blotting (c), and immunocytochemistry/H-score analysis (D,e) that revealed consistent 
upregulation of CD44v3 and CD44v6 isoforms in resistant models.
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were introduced into MCF-7 cells as follows. Briefly, cells at 
50% confluency were incubated with transfection lipid alone 
(FuGENE 6, Promega, UK) or with transfection lipid plus the 
DNA plasmid construct (100 ng/well at 3:1 lipid:DNA ratio) in 
culture medium for 48 h after which cells were harvested and 
used in the assays described.
resUlTs
cD44v3 and cD44v6 are Overexpressed in 
acquired Tamoxifen- and  
Fulvestrant-resistant Breast cancer cells
An initial interrogation of our in-house microarray database was 
performed to identify members of the wider hyaladherin family, 
as well as CD44 itself, that may be deregulated in acquired resist-
ance compared to their drug-sensitive counterparts (Figure 1A). 
These data pointed to an upregulation of both CD44 and recep-
tor for HA-mediated motility (HMMR/RHAMM) in Tam-R 
and Fas-R models compared to MCF-7 cells, while expression 
of other hyaladherin members, LYVE-1, TL4, STAB-2, ICAM-
1, and VCAN were suppressed. As the microarray probe sets 
could not differentiate between CD44 isoforms, RT-PCR was 
performed to explore whether specific CD44 isoforms (specifi-
cally CD44v3 and CD44v6) were altered in addition to global 
CD44 expression. RT-PCR confirmed the microarray data 
showing upregulation of global CD44 transcripts and further 
revealed elevated expression of CD44v3 and CD44v6 isoforms 
in the resistant models (Figure  1B). Elevated levels of CD44, 
v3, and v6 isoforms were subsequently confirmed at the protein 
level by Western blotting that revealed higher levels of CD44 Std 
(80 kDa), CD44v3 (85 kDa), and CD44v6 (85–200 kDa) in Tam-R 
and Fas-R cells versus their MCF-7 counterparts (Figure  1C). 
Immunocytochemical staining of CD44 Std and CD44v6 isoforms 
revealed predominant cell surface staining in contrast to CD44v3 
proteins that revealed intense cytoplasmic staining (Figure 1D). 
Quantitation of staining by H-score revealed a CD44 distribution 
profile across the cell lines largely reflecting the Western data, 
with overexpression of CD44 and its variants in the resistant cells 
compared to their endocrine-sensitive counterparts. Cytoplasmic 
expression appeared similar although CD44v3 levels appeared 
only modestly elevated in Tam-R cells in contrast to the Western 
data (Figure 1E).
inhibition of cD44 suppresses the 
aggressive Phenotype of  
endocrine-resistant Breast cancer cells
Our previous research has shown that endocrine resistance is 
accompanied by aggressive cellular behavior (23) and confirmed 
in this study (Figure 2A). To begin to understand the contribution 
of CD44 variants to cellular phenotype in the context of acquired 
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FigUre 2 | sirna-mediated cD44 suppression reduces the aggressive behavior of endocrine-resistant breast cancer cell models. (a) Tam-R and 
Fas-R cells display enhanced migratory, invasive, and proliferative capacity compared to MCF-7 cells. (B) Western blotting demonstrated that treatment of Tam-R 
and Fas-R cells with CD44-siRNA resulted in suppression of CD44s, CD44v3, and CD44v6 isoforms and global CD44 loss was confirmed by immunocytochemistry 
(c). Suppression of CD44 expression subsequently resulted in loss of invasive (D), migratory (e), and proliferative responses (F) in Tam-R and Fas-R cells.
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endocrine resistance, we first suppressed all forms of endogenous 
CD44 in Tam-R and Fas-R cells using siRNA (Figures 2B,C). This 
resulted in a reduction in the intrinsic migratory, proliferative, 
and invasive nature of both resistant cell lines (Figures 2D–F).
cD44-sirna reduces egFr and Met 
Pathway activity in Tam-r and Fas-r 
cells, respectively
Growth factor receptor pathway activity is suggested to play an 
important role in resistance with previous reports implicating 
the EGFR/HER2 (3, 24) and c-Met (7) pathways in acquired 
tamoxifen and fulvestrant resistance respectively where they may 
contribute to an enhanced migratory phenotype. Since CD44 
can act as a co-receptor for receptor tyrosine kinases (25–27) 
we investigated whether signaling through these receptors was 
affected in the absence of CD44. Western blotting revealed that, 
following suppression of CD44 expression by siRNA, there was 
a reduction of endogenous EGFR and associated signaling path-
way activity in Tam-R cells (Figure 3A). While no effects were 
seen on EGFR signaling in Fas-R cells, suppression of CD44 in 
these cells reduced the activity of the Met receptor (Figure  3) 
previously implicated in Fas-R cell migratory responses (7). 
Accompanying this decrease was a suppression of MAPK and 
AKT in both cell lines; no changes were observed in total levels 
of these proteins (Figure 3).
rhaMM Does not contribute to the 
aggressive Phenotype of  
endocrine-resistant Breast cancer cells
In light of reports that suggest a role for HMMR (RHAMM) in 
tumor progression (28, 29), we investigated whether RHAMM was 
contributory toward the endocrine-resistant phenotype of Tam-R 
and Fas-R cells. Our previous affymetrix data suggested upregula-
tion of RHAMM gene expression in both endocrine-resistant cell 
models; however, confirmation of RHAMM protein expression 
by Western blotting revealed a similar level of expression across 
our cell models (Figure 4A). Immunocytochemistry confirmed 
these findings and showed slightly reduced RHAMM expression 
in both endocrine-resistant cells compared to MCF-7 cells and 
revealed predominant cytoplasmic expression of RHAMM across 
our cell models (Figure 4B). RHAMM suppression by siRNA did 
not modulate the expression of CD44 proteins (Figure 4C) and 
did not alter the aggressive nature of Fas-R cells; interestingly, 
a reduced level of proliferation was observed in Tam-R cells 
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FigUre 4 | inhibition of rhaMM expression does not alter the aggressive behavior of endocrine-resistant breast cancer cells. (a) Western blotting 
revealed a similar level of RHAMM protein expression across MCF-7, Tam-R, and Fas-R cells, which was confirmed by immunocytochemistry and H-score analysis. 
(B). Suppression of RHAMM by siRNA (c), confirmed with immunocytochemical staining and Western blotting, did not alter CD44 variant isoform expression. 
RHAMM suppression did not alter the invasive (D) or migratory (e) capacity of Tam-R and Fas-R cells although some suppression of Tam-R proliferation was 
observed in the absence of RHAMM (F).
A B
FigUre 3 | inhibition of cD44 expression suppresses endogenous growth factor pathway activity in Tam-r and Fas-r cells. Western blotting analysis 
was used to determine the effects of CD44 suppression on signaling activity in Tam-R and Fas-R cells. (a) CD44 suppression reduced EGFR, ErbB2, and MAPK 
phosphorylation in Tam-R cells and reduced Met, AKT, and MAPK phosphorylation in Fas-R cells. (B) No change in total protein levels was observed.
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after RHAMM knockdown (Figures 4D–F). Western blotting of 
cells following suppression of RHAMM by siRNA revealed that 
removal of RHAMM did not affect intrinsic receptor tyrosine 
kinase signaling in Tam-R cells (Figure  5); a similar case was 
seen for Fas-R cells, although a small reduction was observed in 
Met and FAK activity.
FigUre 5 | effects of rhaMM suppression on pathway signaling. Western blotting of cells following treatment with RHAMM siRNA revealed that RHAMM 
suppression did not significantly alter receptor tyrosine kinase and associated pathway signaling in Tam-R cells; however, Fas-R cells showed modest reductions in 
Met and FAK activity. No change in total protein levels was observed in the absence of RHAMM.
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Overexpression of cD44v6, but not 
cD44v3, in McF-7 cells Promotes cellular 
invasion and attenuates endocrine 
response
Our siRNA data suggest that CD44 per se plays an important role 
in mediating the aggressive phenotype of acquired endocrine-
resistant breast cancer cells. However, many CD44 isoforms exist 
and it is not clear regarding which of these are the dominant 
contributors in the context of endocrine resistance. To further 
validate a role for CD44 in the development of an aggressive 
breast cancer cell phenotype and to begin to explore any dif-
ferential contribution of CD44 isoforms, we overexpressed 
CD44v3 and CD44v6, two specific isoforms we have shown to 
be upregulated in Tam-R and Fas-R cells, separately in MCF-7 
cells and assessed any changes to cellular phenotype. Transfection 
of MCF-7 cells with CD44v3 or CD44v6 resulted in upregulated 
expression of these isoforms without affecting the expression of 
other CD44 variants (Figure  6A). Overexpression of CD44v6 
resulted in a significant increase in cellular invasion compared to 
untreated MCF-7 cells; however, this effect was not observed in 
MCF-7 cells overexpressing CD44v3 (Figure 6B). Interestingly, 
CD44v3 appeared to also reduce the proliferative and migratory 
capacity of these cells (Figures  6C,D). Our previous findings 
suggested that CD44 expression may limit endocrine response 
in breast cancer cells (23). To investigate this further, specifically 
in the context of CD44 isoforms, the growth of CD44 isoform-
transfected cells was determined in the presence of tamoxifen and 
fulvestrant. Our data revealed that while CD44v3 overexpression 
in MCF-7 cells did not significantly alter their response to these 
agents, overexpression of CD44v6 attenuated the ability of MCF-7 
cells to respond to fulvestrant resulting in enhanced proliferative 
capacity of these cells (Figure 6E). No changes in CD44 variant 
expression were observed in response to endocrine treatment 
(data not shown).
Overexpression of cD44v6 Promotes 
egFr signaling in McF-7 cells
Given that our data demonstrated suppression of CD44 inhibited 
the endogenous activity of the EGFR and Met pathways in our 
endocrine-resistant cells, we explored the hypothesis that overex-
pression of CD44 variants in MCF-7 cells might augment growth 
factor pathway activity. Overexpression of CD44v3 resulted in 
a modest reduction in ErbB receptor phosphorylation and an 
increase in AKT and Src activity (Figure 7A). By contrast, MCF-7 
cells overexpressing CD44v6 possessed substantially enhanced 
EGFR, AKT, and MAPK phosphorylation; however, Met activity 
was reduced. No changes were seen in the level of total proteins 
expressed. These data suggested that CD44v6 may promote an 
aggressive, endocrine-desensitized phenotype in MCF-7 cells 
through the activation of the EGFR pathway. To explore this hypoth-
esis, we investigated the sensitivity of CD44v6-overexpressing 
MCF-7 cells (MCF-7-CD44v6) to the EGFR inhibitor, gefitinib, 
with respect to their invasive capacity. Gefitinib inhibited the 
invasive nature of MCF-7-CD44v6 cells (Figure 7B) and reduced 
the endogenous activity of EGFR pathway components without 
affecting total levels of these proteins (Figure 7C).
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overexpression, we extended our studies into the resistant mod-
els in which we specifically inhibited CD44v6 expression, using 
siRNA, to explore the hypothesis that CD44v6 plays a key role in 
the aggressive phenotype of endocrine resistance. Western blot-
ting revealed that CD44v6 siRNA was specific for this isoform in 
Tam-R and Fas-R cells (Figures 8A,B). CD44v6 siRNA reduced 
the endogenous invasive and proliferative capacity of Tam-R but 
not Fas-R cells (Figures 8C,D). An increase in cellular migration 
was seen in Tam-R cells following loss of CD44v6 (Figures 8E). 
Accompanying this was a reduction in EGFR pathway components 
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in Tam-R cells and suppressed Met and AKT signaling in Fas-R 
cells, however, total protein levels were unaffected (Figure 8F).
cD44v6 and egFr co-expression 
is associated with a Worsened Outcome 
in Breast cancer Patients
In light of our in vitro evidence that CD44v6 represented a poten-
tial contributory factor to the aggressive phenotype of endocrine-
resistant cells through its ability to modulate EGFR signaling, 
we explored this hypothesis further in a small exploratory series 
of formalin-fixed paraffin-embedded TMAs representing 140 
patients with ER+ primary breast cancers receiving adjuvant 
tamoxifen with a 20-year follow-up and for which the EGFR 
status was already known (30). X-tile was used to define optimal 
CD44v6 membrane cut point (H-score of 47) versus patient 
outcome and statistical testing was performed using Log Rank 
(Mantel–Cox). Of the 140 TMA’s studied in this series, 20 were 
negative for CD44v6 membrane expression. After the cutpoint 
was applied, 71/140 showed TMAs where CD44v6 staining was 
greater than the H-score cutpoint (Figure  9A). Interestingly, 
tumors highly positive for CD44v6 but having reduced or 
absent EGFR appeared to be associated with the most favorable 
DFI; the impact of co-expression of the EGFR in the CD44v6 
cohort was to significantly reduce patient DFI (Figure  9B); 
Mean survival (months ± SD) = 141.9 ± 7.3 [CD44v6+/EGFR−] 
versus 105.6 ±  23.4 (CD44v6+/EGFR+), p <  0.05. A similar 
observation was apparent for tumors expressing EGFR in the 
context of reduced/absent CD44v6 where co-expression resulted 
in a significantly less favorable DFI than EGFR alone; Mean 
survival (months  ±  SD)  =  130.0  ±  23.4 [EGFR+/CD44v6−] 
versus 105.6 ± 23.4 [EGFR+/CD44v6+], p < 0.05. Tumors with 
co-expression of CD44v6 and EGFR had a similar DFI to those 
absent for both markers. Cox regression (C) revealed that tumors 
with a CD44v6+/EGFR+ phenotype were more associated with 
a poorer outcome versus grade although this was not significant.
DiscUssiOn
Although current endocrine treatments for ER+ breast cancers 
work well, the phenomenon of acquired resistance still represents 
a major limiting factor in their overall effectiveness and resistant 
disease frequently occurs at distant sites with associated poor 
prognosis. Since acquisition of endocrine resistance is accom-
panied by a gain in aggressive cellular features that may drive 
distant spread, an understanding of the molecular mechanisms 
that contribute to this behavior may reveal novel therapeutic tar-
gets through which breast cancer outcome can be improved. We 
have previously shown that the standard form of the cell surface 
adhesion receptor, CD44, is overexpressed in Tam-R MCF-7 cells. 
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FigUre 9 | cD44v6 and egFr co-expression reduces DFi in tamoxifen-treated er+ breast cancers. CD44v6 expression was determined in a TMA series 
(n = 140) of ER+ breast cancer patients that had received tamoxifen and for whom their EGFR status was known. (a) Representative images of high (H-score >47) 
and low (H-score <47) CD44v6 staining in TMAs and the associated frequency of the four possible phenotypes encountered in this TMA series. (B) Kaplan–Meier 
survival plots for the four possible phenotypes demonstrating that co-expression of CD44v6 and EGFR (or lack of both) were associated with the poorest DFI. 
(c) Cox regression analysis suggested the CD44v6+/EGFR+ phenotype to be more associated with poorer outcome versus grade although this was not significant.
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Here, we have extended these investigations to a further model 
of acquired fulvestrant resistance and also demonstrate the 
importance of the CD44v6 isoform as a mediator of their invasive 
phenotype and growth factor (EGFR) signaling in these models.
Our initial investigations revealed that, along with CD44, 
RHAMM was upregulated in acquired endocrine resistance. 
Interestingly, while suppression of CD44 by siRNA led to a 
corresponding reduction in RHAMM in both Tam-R and Fas-R 
cells, the converse was not seen, i.e., that modulation of RHAMM 
by siRNA did not affect CD44 expression. Moreover, RHAMM 
suppression did not affect the invasive, migratory, or prolifera-
tive nature of these cells. Taken together, this suggests that the 
aggressive phenotype in our resistant cell models is not depend-
ent upon RHAMM. Subsequently, we investigated the CD44v3 
and v6 isoforms of CD44 given their association with the cancer 
cell phenotype.
CD44v6 is suggested to represent an important prognostic 
marker for some cancer types where its elevated expression is 
associated with metastasis (14, 18). The association between 
CD44v6 and disease progression may stem from its ability to 
augment the activity of growth factor signaling pathways. In our 
study, we investigated changes in the expression and activity of 
a number of receptor tyrosine kinases known to be linked to an 
invasive phenotype. Of these, we observed that CD44v6 expres-
sion was associated with increased EGFR activity in addition to 
AKT and MAPK signaling, whereas Met activity was suppressed. 
Interestingly, Yu et  al. (17) found a strong correlation between 
CD44v6 and AKT expression that was associated with a shorter 
DFS across 98 samples of breast cancer tissues. Furthermore, 
AKT activity is reported to be elevated in CD44v6-overexpressing 
tumors (31), while CD44v6 is able to activate MAPK signaling 
in combination with other growth factor receptors (32, 33). Our 
data suggest that CD44v6 expression in some way activates EGFR 
signaling; we tested this hypothesis by challenging CD44v6+ cells 
with the EGFR inhibitor, gefitinib. Subsequently, our data showed 
that gefitinib was able to suppress the invasive capacity of these 
cells to that of the control levels (Figure 7B) and also prevented 
the increase in EGFR, AKT, and MAPK observed following 
CD44v6 overexpression (7C). Given the literature supporting 
CD44 interactions with other RTKs, there is the possibility that 
CD44v6 may interact with other receptors in our cell models 
promoting downstream signaling and an invasive response. 
However, our data do suggest that irrespective of this, the EGFR 
represents a dominant pathway given the ability of EGFR path-
way inhibition to circumvent CD44v6 effects. Similar findings 
have been reported by others where interactions between CD44 
and erbB members increase cell motility (34–36) while our data 
additionally point to the co-expression of EGFR and CD44v6 
as a clinically relevant phenomenon albeit in a small cohort of 
patients (Figure 9). Although our Cox regression analysis failed 
to demonstrate further significance of the CD44v6/EGFR pheno-
type, this is likely due to the low numbers (n = 9) in this subset 
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and further investigation of CD44v6 ± EGFR in a larger number 
may well reveal a more clearer association with outcome.
Importantly, our data allude to the potential role for CD44v6 in 
chemoresistance where its overexpression limits cellular response 
of ER+ endocrine-sensitive cells to fulvestrant. Recent reports 
have suggested a role between CD44v6 and chemoresistance 
in prostate cancer which may involve AKT pathway activation 
(31). Furthermore, a function of CD44v6 as a cell cycle regulator 
has been suggested potentially through its ability to modulate 
the Hippo effector, YAP, known to indirectly regulate cell cycle 
progression (37). Studies that have used combination treatments 
to suppress cell growth through cell cycle inhibition show that 
CD44v6 is also reduced in response to these treatments (38). 
These observations may explain to some degree our observations 
that CD44v6-overexpressing MCF-7 cells fail to respond to fulves-
trant, with CD44v6 providing an indirect, positive input into cell 
cycle in the presence of fulvestrant. Given the interplay between 
CD44 and RTKs and the well-established cross talk between 
RTKs and the ER, it may further be that CD44 upregulation can 
indirectly activate or modulate the expression of the ER thereby 
limiting the sensitivity to endocrine agents. While an interesting 
hypothesis, this did not appear to be the case here as no change 
in ER expression or activity was seen in MCF-7 or Tam-R cells 
following CD44 manipulation; Fas-R cells are ER- (39) and no 
ER restoration was observed following CD44-siRNA (Bellerby, 
unpublished observations).
While our data suggest an important role for CD44v6 in the 
aggressive behavior of our endocrine-resistant cells, it is important 
to note a global knockdown of CD44 expression in both resistant 
cell models results in differential effects: while Tam-R cells lose 
their proliferative, invasive, and migratory capacity, only the 
invasive behavior is affected in Fas-R cells. One explanation for 
this may be the differential expression of growth factor receptors 
that accompany different forms of acquired resistance and, thus, 
provide different interacting partners for the CD44 isoforms. 
However, that CD44 can be suppressed to attenuate aggressive 
behavior irrespective of the resistant background suggests that its 
targeting may be of value.
Whilst CD44 overexpression is widely reported in a number 
of different tumor types where it correlates with advanced stage/
higher grade, such studies invariably use experimental approaches 
that are unable to differentiate between individual CD44 isoforms, 
masking the true pattern of CD44 isoform expression. Indeed the 
fact that some studies suggest a relationship between expression 
of CD44 standard or its variant isoforms with respect to prognosis 
(40–42), while other reports are less clear as to a relationship 
between CD44 and outcome (43–46) is likely due to the com-
plexities of the CD44 expression pattern and the ability to clearly 
differentiate between different isoforms; our data further point to 
the importance of understanding the complexities of CD44 vari-
ant expression rather than CD44 per se in breast cancer. Recent 
studies have demonstrated the importance of this, showing that a 
combination of CD44v6 and CD44s, but not CD44 alone, is able 
to predict survival in lung cancer patients (47), while pancreatic 
tumors with a “CD44v6+/CD44−” profile are more metastatic 
(41). Not only will understanding the contribution of specific 
CD44 isoforms to tumor progression/suppression be beneficial 
in developing prognostic markers but it may also reveal specific 
variants that may have therapeutic potential.
The v6 variant of the CD44 family is known to be highly 
expressed in invasive breast cancers (48) and has itself been the 
subject of investigation with respect to its therapeutic potential. 
While in recent years, these approaches have been met with 
some success in multiple carcinomas, including pancreatic 
(49), colon (50), and prostate (51) their effectiveness in breast 
cancer remains limited. However, the identification of CD44 as 
a marker of breast cancer stem cells has led to the development 
of a novel strategy through which to target CD44 and, thus, the 
subpopulation of stem-like cells that may reside in such tumors 
(52). Recently, the ability to exploit CD44 as a drug-delivery 
system in cancers, including breast has been investigated with 
encouraging results (53–55). Thus, the ability to identify specific 
CD44 isoforms that contribute to the progression of breast 
cancers offers a potential prognostic and therapeutic target in 
such tumors. Our data support the role of CD44v6 in breast 
cancer, particularly in the context of relapsed disease and suggest 
that therapeutically targeting this isoform may be of benefit in 
such contexts.
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